Literature DB >> 27337486

Herpes Simplex Virus and Varicella-Zoster Virus.

Myron J Levin1, Adriana Weinberg2, D Scott Schmid3.   

Abstract

The most common specimens from immunocompromised patients that are analyzed for detection of herpes simplex virus (HSV) or varicella-zoster virus (VZV) are from skin lesions. Many types of assays are applicable to these samples, but some, such as virus isolation and direct fluorescent antibody testing, are useful only in the early phases of the lesions. In contrast, nucleic acid (NA) detection methods, which generally have superior sensitivity and specificity, can be applied to skin lesions at any stage of progression. NA methods are also the best choice, and sometimes the only choice, for detecting HSV or VZV in blood, cerebrospinal fluid, aqueous or vitreous humor, and from mucosal surfaces. NA methods provide the best performance when reliability and speed (within 24 hours) are considered together. They readily distinguish the type of HSV detected or the source of VZV detected (wild type or vaccine strain). Nucleic acid detection methods are constantly being improved with respect to speed and ease of performance. Broader applications are under study, such as the use of quantitative results of viral load for prognosis and to assess the efficacy of antiviral therapy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27337486     DOI: 10.1128/microbiolspec.DMIH2-0017-2015

Source DB:  PubMed          Journal:  Microbiol Spectr        ISSN: 2165-0497


  8 in total

1.  [Acral ulcers in a man with chronic lymphocytic leukemia].

Authors:  Saskia Lehr; Frank Meiss; Christoph M Schempp
Journal:  Hautarzt       Date:  2021-06       Impact factor: 0.751

2.  Expression and correlation of IL-2, IL-10 and TNF-α in patients with multiple myeloma-infected herpes zoster treated by bortezomib-containing regimen.

Authors:  Kang Liu; Yafei Yin; Xinfu Zhou; Kaibo Zhu; Zimian Luo
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 3.  Fraternal Twins: The Enigmatic Role of the Immune System in Alphaherpesvirus Pathogenesis and Latency and Its Impacts on Vaccine Efficacy.

Authors:  Barry T Rouse; D Scott Schmid
Journal:  Viruses       Date:  2022-04-21       Impact factor: 5.818

4.  Population Pharmacokinetics of Intravenous and Oral Acyclovir and Oral Valacyclovir in Pediatric Population To Optimize Dosing Regimens.

Authors:  S Abdalla; C Briand; M Oualha; M Bendavid; A Béranger; S Benaboud; J-M Tréluyer; Y Zheng; C Capito; Z Demir; F Foissac; S Winter; I Gana; S Boujaafar; N Bouazza; D Hirt
Journal:  Antimicrob Agents Chemother       Date:  2020-11-17       Impact factor: 5.191

5.  Bayesian Evaluation of Solana HSV 1+2/VZV Assay Compared to Viral Culture and Commercial PCR Assay for Cutaneous or Mucocutaneous Specimens.

Authors:  Christine Arsenault; Félix Camirand Lemyre; Philippe Martin; Simon Lévesque
Journal:  J Clin Microbiol       Date:  2020-02-24       Impact factor: 5.948

6.  Herpesvirus Infections and Risk of Parkinson's Disease.

Authors:  Alejandra Camacho-Soto; Irene Faust; Brad A Racette; David B Clifford; Harvey Checkoway; Susan Searles Nielsen
Journal:  Neurodegener Dis       Date:  2021-01-18       Impact factor: 2.977

Review 7.  Persistence of Pathogens on Inanimate Surfaces: A Narrative Review.

Authors:  Jan Erik Wißmann; Lisa Kirchhoff; Yannick Brüggemann; Daniel Todt; Joerg Steinmann; Eike Steinmann
Journal:  Microorganisms       Date:  2021-02-09

8.  Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus.

Authors:  Larissa Henze; Christoph Buhl; Michael Sandherr; Oliver A Cornely; Werner J Heinz; Yascha Khodamoradi; Til Ramon Kiderlen; Philipp Koehler; Alrun Seidler; Rosanne Sprute; Martin Schmidt-Hieber; Marie von Lilienfeld-Toal
Journal:  Ann Hematol       Date:  2022-01-07       Impact factor: 3.673

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.